Finerenone is a nonsteroidal antimineralocorticoid that is in phase III clinical trials for the treatment of chronic kidney disease in people with type II diabetes.
Trade name Kerendia
It has less relative affinity to other steroid hormone receptors than currently available antimineralocorticoids such as eplerenone and spironolactone, which should result in fewer adverse effects like gynaecomastia, impotence, and low libido.
Routes of administration Oral
Pregnancy category AU: D
Finerenone blocks mineralocorticoid receptors, which makes it a potassium-sparing diuretic.
Finerenone, used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes.
Unlike currently marketed antimineralocorticoids, finerenone is not a steroid but a dihydropyridine derivative.
In the Phase II ARTS-DN study, finerenone dose-dependently reduces urine albumin to creatinine ratio in patients with diabetic kidney disease.
Among patients with type two diabetes and stage 2 to 4 chronic kidney disease with moderate elevated albuminuria or stage one or two chronic kidney disease with severely elevated albuminuria, finerenone improves cardiovascular outcomes is compared with placebo.
Common side effects include hyperkalemia, hypotension and hyponatremia.
Finerenone has less relative affinity to other steroid hormone receptors than currently available aldosterone antagonists such as eplerenone and spironolactone, which should result in fewer adverse effects like gynaecomastia, impotence, and low libido.
In the Phase II ARTS-DN study, finerenone dose-dependently reduced urine albumin to creatinine ratio in patients with diabetic kidney disease.